Retrospective analysis of three induction chemotherapy regimens in acute myeloid leukemia including CPX-351, cytarabine/daunorubicin with and without the addition of cladribine-Reference-Cited by-同舟云学术

Retrospective analysis of three induction chemotherapy regimens in acute myeloid leukemia including CPX-351, cytarabine/daunorubicin with and without the addition of cladribine

Published:2022-07-05 Issue:11 Volume:63 Page:2645-2651
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Klingler Felix¹,Alsdorf Winfried H.¹,Ghandili Susanne¹,Wolschke Christine²,Brauneck Franziska¹³^ORCID,Bokemeyer Carsten¹,Fiedler Walter¹,Modemann Franziska¹³,Karagiannis Panagiotis¹^ORCID

Affiliation:

1. Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

2. Department of Stem cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

3. Mildred Scheel Cancer Career Center, University Cancer Center Hamburg, Hamburg, Germany

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2022.2092855

Reference19 articles.

1. Acute Myeloid Leukemia

2. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with aFLT3Mutation

3. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial

4. How I treat acute myeloid leukemia in the era of new drugs

5. The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance])

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world experience with CPX-351 in high-risk acute myeloid leukemia;Critical Reviews in Oncology/Hematology;2023-05

2. Cytarabine/daunorubicin;Reactions Weekly;2023-02-18